Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
Kollmar
Otto
O
Becker
Sandra
S
Schilling
Martin K
MK
Maurer
Christoph A
CA
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D007416:Intestinal Perforation / Q000139:chemically induced*; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab; D011239:Prednisolone